Sudden Fall in the Lipid-Lowering Effect of Evolocumab: The Butler Is Not Always Guilty
A 78-year-old man came to our attention after undergoing coronary computed tomography angiography documenting multivessel coronary artery disease. He was started on treatment with the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor evolocumab 140 mg subcutaneously every 2 weeks. Trea...
Сохранить в:
| Главные авторы: | , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
MDPI AG
2021-08-01
|
| Серии: | Medicina |
| Предметы: | |
| Online-ссылка: | https://www.mdpi.com/1648-9144/57/9/857 |
| Метки: |
Нет меток, Требуется 1-ая метка записи!
|